256
Participants
Start Date
February 18, 2022
Primary Completion Date
October 30, 2026
Study Completion Date
December 30, 2026
Afuresertib
The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
Afuresertib/placebo
afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
RECRUITING
Virginia Cancer Specialists, Fairfax
COMPLETED
Piedmont Cancer Institute, Atlanta
COMPLETED
University of Mississippi Medical Center, Jackson
COMPLETED
University of Iowa, Iowa City
COMPLETED
Providence St. Johns Health Center, Santa Monica
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Peking Union Medical College Hospital (PUMCH), Beijing
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
The first hospital of Jilin University, Changchun
RECRUITING
Jilin Provincial Cancer Hospital, Changchun
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
Zhongshan Hospital, Fudan University, Shanghai
RECRUITING
Jiangsu Cancer Hospital, Nanjing
RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
RECRUITING
Northern Jiangsu People's Hospital, Yangzhou
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
Sir-run shaw Hospital Zhejiang University of Medicine, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Ningbo Li Huili Hospital, Ningbo
RECRUITING
Taizhou Hospital, Taizhou
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Wuhan Central Hospital, Wuhan
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Anyang cancer hospital, Anyang
RECRUITING
Sun Yat-sen Memorial Hospital，Sun Yat-sen University, Guangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
The First People's Hospital of Foshan, Foshan
RECRUITING
Zhongshan People's Hospital, Zhongshan
RECRUITING
Guangxi Zhuang Autonomous Region People's Hospital, Nanning
RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Nanning
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Sichuan Provincial People's Hospital, Chengdu
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
COMPLETED
University of Vermont, Burlington
RECRUITING
Affiliated Hospital of Hebei University, Baoding
RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
Tangshan People's Hospital, Tangshan
RECRUITING
Affiliated Hospital of Nantong University, Nantong
Laekna Limited
INDUSTRY